Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

This study is testing an experimental drug called LP-300 alongside standard chemotherapy to see if it helps people with advanced lung cancer live longer and prevents the cancer from growing. Researchers want to find out if adding this new drug works better than using chemotherapy alone for patients who have never smoked.

This study is for adults with advanced adenocarcinoma (a type of lung cancer) who have never smoked and have already tried targeted therapy without success. You must have lung cancer that cannot be removed by surgery and meet specific health requirements confirmed by your doctor.

Participants will receive the experimental drug LP-300 combined with standard chemotherapy drugs called carboplatin and pemetrexed. You will be closely monitored by the study team throughout the trial to check how your body responds to the treatment and to manage any side effects.

This study is currently recruiting patients at medical centers in Beverly Hills, Fountain Valley, and Los Alamitos, California. It is a Phase II trial designed to enroll 90 people across the United States.